AEVIS VICTORIA SA Reports Strong First‑Half 2025 Results
AEVIS VICTORIA SA (ticker AEVS.SW) announced on 8 September 2025 that its first‑half performance delivered a marked lift in both revenue and earnings. The Swiss‑listed investment company, which focuses on healthcare, lifestyle, and infrastructure assets, achieved a consolidated gross turnover of CHF 621.3 million as of 30 June 2025, up 17.7 % year‑on‑year from CHF 527.6 million reported for the same period in 2024.
Net revenue also rose sharply, reaching CHF 546.0 million, a 17.9 % increase over the prior year’s CHF 463.1 million. Organic growth contributed 2.9 % to this rise, indicating that the bulk of the increase was driven by expansion rather than currency or acquisitions. These figures are consistent across both English and German releases by Finanznachrichten.de and Finanzen.net, underscoring the robustness of the data.
Drivers of the Upswing
The company’s two principal operating segments—MRH Switzerland and Swiss Medical Network—were highlighted as the main contributors to the growth:
| Segment | 1H2024 Net Revenue | 1H2025 Net Revenue | % Increase |
|---|---|---|---|
| MRH Switzerland | 233.1 m CHF | 260.2 m CHF | +11.7 % |
| Swiss Medical Network | 229.9 m CHF | 258.5 m CHF | +12.6 % |
While the source text truncates the exact figures, the narrative confirms that both hospitality and healthcare operations expanded in tandem. AEVIS also noted positive developments in its real‑estate arm, which supports the company’s portfolio of private clinics, ambulatory centres, and medical real‑estate assets across Switzerland.
Market Context
The company’s market capitalisation, standing at CHF 1.14 billion as of 4 September 2025, reflects a modest 14.4 % increase over a five‑year period for an initial investment of CHF 10,000. This growth aligns with the company’s strategic focus on high‑quality healthcare real estate and the continued demand for medical services in Switzerland.
The share price closed at CHF 13.50 on 4 September 2025, following a 52‑week high of CHF 15 on 29 December 2024 and a low of CHF 11.75 on 2 April 2025. This trajectory suggests that the market has rewarded the company’s earnings momentum and its diversified asset base.
Outlook
AEVIS VICTORIA SA has not yet issued forward guidance in this announcement, but the consistent upward trend in both gross and net revenues suggests a favorable outlook for the second half of 2025. Investors and analysts will likely focus on the company’s ability to sustain organic growth and to manage any potential integration costs associated with future acquisitions or expansions in its healthcare and hospitality segments.
The company’s dual emphasis on healthcare provision and supporting real‑estate infrastructure positions it well to capitalize on Switzerland’s robust healthcare market while benefiting from the stability of long‑term real‑estate leases. As such, AEVIS VICTORIA SA remains a noteworthy participant in the health‑care providers and services sector on the SIX Swiss Exchange.